These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 15566356)
1. Effect of IL-2R beta-binding cytokines on costimulatory properties of chronic lymphocytic leukaemia cells: implications for immunotherapy. Spaner DE; Hammond C; Mena J; Shi Y Br J Haematol; 2004 Dec; 127(5):531-42. PubMed ID: 15566356 [TBL] [Abstract][Full Text] [Related]
2. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation. Trentin L; Perin A; Siviero M; Piazza F; Facco M; Gurrieri C; Galvan S; Adami F; Agostini C; Pizzolo G; Zambello R; Semenzato G Cancer; 2000 Sep; 89(6):1259-68. PubMed ID: 11002221 [TBL] [Abstract][Full Text] [Related]
3. IL-13 has only a subset of IL-4-like activities on B chronic lymphocytic leukaemia cells. Fluckiger AC; Brière F; Zurawski G; Bridon JM; Banchereau J Immunology; 1994 Nov; 83(3):397-403. PubMed ID: 7530690 [TBL] [Abstract][Full Text] [Related]
4. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A. Mukherjee S; Ahmed A; Nandi D J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440 [TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718 [TBL] [Abstract][Full Text] [Related]
6. Modulation of cell cycle progression by CTLA4-CD80/CD86 interactions on CD4+ T cells depends on strength of the CD3 signal: critical role for IL-2. Mukherjee S; Ahmed A; Malu S; Nandi D J Leukoc Biol; 2006 Jul; 80(1):66-74. PubMed ID: 16624934 [TBL] [Abstract][Full Text] [Related]
7. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis. Marckmann S; Wiesemann E; Hilse R; Trebst C; Stangel M; Windhagen A Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628 [TBL] [Abstract][Full Text] [Related]
8. Release of interleukin-6 in cultured B-chronic lymphocytic leukaemia cells is associated with both activation and cell death via apoptosis. Büssing A; Stein GM; Stumpf C; Schietzel M Anticancer Res; 1999; 19(5B):3953-9. PubMed ID: 10628337 [TBL] [Abstract][Full Text] [Related]
9. Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro. Tretter T; Schuler M; Schneller F; Brass U; Esswein M; Aman MJ; Huber C; Peschel C Cell Immunol; 1998 Oct; 189(1):41-50. PubMed ID: 9758693 [TBL] [Abstract][Full Text] [Related]
10. Mitogen induced activation, proliferation and surface antigen expression patterns in unmutated and hypermutated chronic lymphocytic leukemia cells. Vilpo J; Tobin G; Hulkkonen J; Hurme M; Thunberg U; Sundström C; Vilpo L; Rosenquist R Eur J Haematol; 2005 Jul; 75(1):34-40. PubMed ID: 15946308 [TBL] [Abstract][Full Text] [Related]
12. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity. Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231 [TBL] [Abstract][Full Text] [Related]
13. In vitro cytokine-primed leukaemia cells induce in vivo T cell responsiveness in chronic myeloid leukaemia. Lim SH; Coleman S; Bailey-Wood R Bone Marrow Transplant; 1998 Dec; 22(12):1185-90. PubMed ID: 9894722 [TBL] [Abstract][Full Text] [Related]
15. Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemia. Allgeier T; Garhammer S; Nössner E; Wahl U; Kronenberger K; Dreyling M; Hallek M; Mocikat R Cancer Lett; 2007 Jan; 245(1-2):275-83. PubMed ID: 16516377 [TBL] [Abstract][Full Text] [Related]
16. B-chronic lymphocytic leukemia cells exert an in vitro cytotoxicity mediated by tumor necrosis factor alpha. Rosati E; Sabatini R; Tabilio A; Di Ianni M; Bartoli A; Marconi P Leuk Res; 2005 Jul; 29(7):829-39. PubMed ID: 15927678 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Lai R; O'Brien S; Maushouri T; Rogers A; Kantarjian H; Keating M; Albitar M Cancer; 2002 Sep; 95(5):1071-5. PubMed ID: 12209693 [TBL] [Abstract][Full Text] [Related]
18. Direct or reverse correlations within the expression of activation, differentiation or T-B cooperation molecules on chronic lymphocytic leukemia B cells. Sellitto A; De Fanis U; Romano C; Dalla Mora L; Guastafierro S; Tirelli A; Lucivero G Minerva Med; 2003 Oct; 94(5):331-6, 336-9. PubMed ID: 14973427 [TBL] [Abstract][Full Text] [Related]
19. Expression levels of CD38 on leukemic B cells but not on non-leukemic T cells are comparably stable over time and predict the course of disease in patients with chronic lymphocytic leukemia. Eisele L; Haddad T; Sellmann L; Dührsen U; Dürig J Leuk Res; 2009 Jun; 33(6):775-8. PubMed ID: 18922578 [TBL] [Abstract][Full Text] [Related]
20. Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells. Li LH; Biagi E; Allen C; Shivakumar R; Weiss JM; Feller S; Yvon E; Fratantoni JC; Liu LN Cancer Gene Ther; 2006 Feb; 13(2):215-24. PubMed ID: 16082377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]